Cargo Therapeutics has got an early boost from its abstract to be presented the European meeting, while Shattuck has suffered on safety doubts for its CD47 inhibitor.
Smaller biopharma companies will have a chance to shine at this year’s European Hematology Association congress, with Cargo Therapeutics and Kymera among those already picked out by analysts as ones to watch ahead of the meeting next month.
Many big pharma datasets at EHA follow on from ASCO presentations – which should give smaller companies room to promote their results
That is because while numerous major studies are due to be presented by big pharma at the EHA in Madrid,...
The osteogenesis imperfecta drug stumbled in a second interim analysis.
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.
Coartem Baby to be rolled out in eight African countries in the autumn.
